51 / 83
E
levated
serum
osteoprotegerin
levels
in
women
:
friend
or
foe
?
R
ev
A
ssoc
M
ed
B
ras
2015; 61(6):524-529
529
35.
Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al.
Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion
progression and calcification in older ApoE-/- mice. Arterioscler Thromb
Vasc Biol. 2006; 26:2117-24.
36.
Browner WS1, Lui LY, Cummings SR. Associations of serum osteoprotegerin
levels with diabetes, stroke, bone density, fractures, and mortality in elderly
women. J Clin Endocrinol Metab. 2001; 86:631-7.
37.
Krzanowski M, Janda K, Dumnicka P, Dubiel M, Stompór M, Ku
ś
nierz-
Cabala B, et al. Relationship between aortic pulse wave velocity, selected
proinflammatory cytokines, and vascular calcification parameters in
peritoneal dialysis patients. J Hypertens. 2014; 32:142-8.
38.
Montecucco F, Steffens S, Mach F. The immune response is involved in
atherosclerotic plaque calcification: could the RANKL/RANK/OPG system
be a marker of plaque instability? Clin Dev Immunol. 2007; 2007:75805.
39.
Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a
predictor of cardiovascular disease: a systematic literature review. Eur J
Endocrinol. 2008; 159:603-8.
40.
Løgstrup BB, Høfsten DE, Christophersen TB, Møller JE, Bjerre M, Flyvbjerg
A, et al. Microvascular dysfunction is associated with plasma osteoprotegerin
levels in patients with acute myocardial infarction. Coron Artery Dis. 2013;
24:487-92.
41.
Mogelvang R, Haahr-Pedersen S, Bjerre M, Frystyk J, Iversen A, Galatius S,
et al. Osteoprotegerin improves risk detection by traditional cardiovascular
risk factors and hsCRP. Heart. 2013; 99:106-10.
42. Andersen GØ, Knudsen EC, Aukrust P, Yndestad A, Oie E, Müller C, et al.
Elevated serum osteoprotegerin levels measured early after acute ST-elevation
myocardial infarction predict final infarct size. Heart. 2011; 97:460-5.
43.
Fuernau G, Zaehringer S, Eitel I, de Waha S, Droppa M, Desch S, et al.
Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact
and association with markers of myocardial damage by magnetic resonance
imaging. Int J Cardiol. 2013; 167:2134-9.
44.
Eren MA, Vural M, Yildiz S, Cece H, Camuzcuoglu H, Toy H, et al. Association
of parity with osteoprotegerin levels and atherosclerosis. Arch Gynecol
Obstet. 2013; 287:1081-6.
45.
Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular
complications. Springerplus. 2013; 2:658.
46.
Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, et al.
Osteoprotegerin increases in metabolic syndrome and promotes adipose
tissue proinflammatory changes. Mol Cell Endocrinol. 2014; 394:13-2.
47. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, et al.
Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B
cell development and function. J Immunol. 2001; 166:1482-91.
48. Zauli G1, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, et al.
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in
vitro and in vivo. Blood. 2007; 110:536-43.
49.
Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. Role of alpha(v) integrin
in osteoprotegerin-induced endothelial cell migration and proliferation.
Microvasc Res. 2008; 4:4.
50.
Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al.
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem.
1998; 273:14363-7.
51. Candido R. The osteoprotegerin/tumor necrosis factor related apoptosis-
inducing ligand axis in the kidney. Curr Opin Nephrol Hypertens. 2014;
23:69-74.